结核活载体疫苗的研究进展  

Advances in the study of tuberculosis live vector vaccines

作　　者：陈敬蕊 周步丹 刘磊[1] 姜秀云[1,2] 

机构地区：[1]吉林农业大学动物科学技术学院,长春130118 [2]长春科技学院生物食品学院,长春130600

出　　处：《中国人兽共患病学报》2017年第1期67-71,共5页Chinese Journal of Zoonoses

基　　金：国家自然科学基金项目(No.31572555);吉林省教育厅"十二五"科学技术研究项目(No.201441)联合资助

摘　　要：目前,用于预防结核病的疫苗仍然是卡介苗(BCG),免疫效果不理想,原因颇为复杂;随着结核耐药菌株的出现,加上艾滋病感染与发病的增加,导致结核病发病人数逐年增多,所以研制新型结核病疫苗迫在眉睫。本文对近几年结核活载体疫苗的研究成果进行总结,为后续研究提供参考。Currently, the BCG is used to prevent tuberculosis,but the immune effect is not ideal due to varied reasons. The existence of drug-resistant strains of tuberculosis and the increased prevalence and incidence of AIDS have leaded to the in- creased incidence of TB year by year. Therefore, the development of new tuberculosis vaccine is imminent. In this paper,the lat- est research results in recent years for tuberculosis live vector vaccines were summarized, which provide a theoretical reference for further research and development of new TB vaccines.

关 键 词：结核分枝杆菌 卡介苗 活载体疫苗 免疫应答 

分 类 号：R378.91[医药卫生—病原生物学]